TL;DR
An unprecedented advisory committee rebellion has recommended expanding compounding access to six unapproved wellness peptides, overriding career FDA scientists who warned of safety risks. Meanwhile, high-stakes regulatory decisions are reaching a head as Moderna's first routine seasonal mRNA vaccine nears its target action date, while the fallout from dramatic advisory votes has left one biotech threatening legal action and another on the verge of a historic turnaround.
An Unprecedented Regulatory Rebellion in Peptide Compounding
Wellness-market demand and shifting administrative priorities are driving federal advisors to override career scientists to expand access to unapproved peptides.
"The FDA's Pharmacy Compounding Advisory Committee (PCAC) closed its July 23-24 meeting with a string of narrow votes recommending 6 of the 7 peptides under review—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for the agency's 503A Bulks List, overriding career scientists who had recommended against including any of the 7." — fda-compounding-advisory-committee-peptide-recommendations
By recommending substances like BPC-157 and TB-500 despite FDA staff warnings about human safety data gaps, the committee has signaled a willingness to prioritize alternative medicine access over traditional clinical trial proof fda-compounding-advisory-committee-peptide-recommendations. This dramatic policy shift potentially aligns with the administrative priorities of HHS Secretary Robert F. Kennedy, Jr., though compounding pharmacies must still wait for formal rulemaking before custom formulation can legally begin fda-compounding-advisory-committee-peptide-recommendations
.
What to watch: Watch whether the FDA implements these advisory recommendations through formal administrative rulemaking to officially update the Section 503A Bulks List fda-compounding-advisory-committee-peptide-recommendations.
Moderna's High-Stakes mRNA Expansion Beyond COVID-19
The commercial viability of routine mRNA therapeutics faces a critical split-screen moment as a major respiratory vaccine nears approval while non-respiratory pipelines falter.
"If the FDA approves mFLUSIVA by that date, it would become Moderna's fifth commercial product and its first vaccine against a routine, annually recurring disease — a commercial milestone that analysts have estimated could contribute $1 billion to the company's coffers by 2028." — moderna-mflusiva-flu-vaccine-fda-pdufa
While the upcoming August 5, 2026, PDUFA date for the seasonal influenza vaccine mFlusiva offers a potential billion-dollar revenue stream, the July 31, 2026, announcement of a norovirus vaccine trial failure highlights the steep technical challenges of extending mRNA technology to non-respiratory pathogens moderna-mflusiva-flu-vaccine-fda-pdufa. Rebuilding the company's respiratory franchise is urgent to offset cash burn as other pipeline candidates stumble moderna-mflusiva-flu-vaccine-fda-pdufa
.
What to watch: Watch for the FDA's final regulatory decision on mFlusiva on or before its August 5, 2026, action date moderna-mflusiva-flu-vaccine-fda-pdufa.
The Bitter Aftermath of the Biologics Advisory Showdowns
The divergent regulatory paths of Capricor and Replimune have culminated in a stark contrast between a potential legal war against the FDA and a historic regulatory turnaround.
"The word of the day seems to be fragile. The results were very fragile. I simply didn’t see enough evidence of benefit to vote yes." — capricor-deramiocel-dmd-cardiomyopathy-fda-review
"Their decision heightens the chance that the FDA will finally approve that treatment, 'RP1,' after twice turning it back." — replimune-rp1-melanoma-fda-review
Building on the regulatory tension noted last week, the July 29, 2026, rejection of Capricor's deramiocel has triggered raw corporate fury, with the CEO threatening legal action over disputed statistical analysis plans capricor-deramiocel-dmd-cardiomyopathy-fda-review. Conversely, Replimune's RP1 secured a 10–3 advisory endorsement on July 30, proving that high unmet clinical need in refractory populations can successfully override intense FDA staff skepticism regarding single-arm trials replimune-rp1-melanoma-fda-review
.
What to watch: Watch whether the FDA adheres to the advisory recommendations for Replimune's RP1 by its August 2, 2026, PDUFA date and Capricor's deramiocel by August 22, 2026 replimune-rp1-melanoma-fda-review, capricor-deramiocel-dmd-cardiomyopathy-fda-review
.
What surprised us
- The total advisory rebellion on compounding peptides. The Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides, including popular wellness compounds BPC-157 and TB-500, despite career FDA scientists formally objecting to all of them due to a lack of human safety data fda-compounding-advisory-committee-peptide-recommendations
.
- Moderna's non-respiratory mRNA struggles. While its seasonal flu vaccine is on the cusp of approval, Moderna's norovirus candidate failed to meet the bar for early success in Phase 3, showing that mRNA's success in respiratory diseases does not easily translate to other pathogens moderna-mflusiva-flu-vaccine-fda-pdufa
.
- The threat of a corporate lawsuit against the FDA. Capricor CEO Linda Marbán's public threat of legal action following a negative advisory vote exposes an unusually hostile rupture between a drug sponsor and federal regulators over statistical trial protocols capricor-deramiocel-dmd-cardiomyopathy-fda-review
.